LT4508045T - Muskarininio receptoriaus agonisto citrato druskos formos - Google Patents
Muskarininio receptoriaus agonisto citrato druskos formosInfo
- Publication number
- LT4508045T LT4508045T LTEPPCT/EP2023/071591T LTEP2023071591T LT4508045T LT 4508045 T LT4508045 T LT 4508045T LT EP2023071591 T LTEP2023071591 T LT EP2023071591T LT 4508045 T LT4508045 T LT 4508045T
- Authority
- LT
- Lithuania
- Prior art keywords
- receptor agonist
- salt forms
- muscarinic receptor
- citrate salt
- citrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2211399.7A GB202211399D0 (en) | 2022-08-04 | 2022-08-04 | Muscarinic receptor agonists |
| GBGB2305444.8A GB202305444D0 (en) | 2023-04-13 | 2023-04-13 | Muscarinic receptor agonists |
| GBGB2309615.9A GB202309615D0 (en) | 2023-06-26 | 2023-06-26 | Muscarinic receptor agonists |
| PCT/EP2023/071591 WO2024028458A2 (en) | 2022-08-04 | 2023-08-03 | Muscarinic receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT4508045T true LT4508045T (lt) | 2025-11-25 |
Family
ID=87696205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/EP2023/071591T LT4508045T (lt) | 2022-08-04 | 2023-08-03 | Muskarininio receptoriaus agonisto citrato druskos formos |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20250340531A1 (lt) |
| EP (2) | EP4663190A2 (lt) |
| JP (1) | JP2025526601A (lt) |
| KR (1) | KR20250041066A (lt) |
| CN (1) | CN119866336A (lt) |
| AR (1) | AR130114A1 (lt) |
| AU (1) | AU2023317835A1 (lt) |
| CA (1) | CA3263797A1 (lt) |
| CL (1) | CL2025000299A1 (lt) |
| CO (1) | CO2025002413A2 (lt) |
| CR (1) | CR20250069A (lt) |
| DK (1) | DK4508045T3 (lt) |
| DO (1) | DOP2025000015A (lt) |
| ES (1) | ES3050097T3 (lt) |
| FI (1) | FI4508045T3 (lt) |
| HR (1) | HRP20251427T1 (lt) |
| IL (1) | IL318739A (lt) |
| LT (1) | LT4508045T (lt) |
| MA (1) | MA69856B1 (lt) |
| MD (1) | MD4508045T2 (lt) |
| MX (1) | MX2025001312A (lt) |
| PE (1) | PE20251236A1 (lt) |
| PT (1) | PT4508045T (lt) |
| RS (1) | RS67422B1 (lt) |
| SI (1) | SI4508045T1 (lt) |
| TW (1) | TW202416955A (lt) |
| WO (1) | WO2024028458A2 (lt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025030095A1 (en) * | 2023-08-03 | 2025-02-06 | Neurocrine Biosciences, Inc. | Methods of synthesis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2882741B1 (en) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| SI3406609T1 (sl) | 2014-02-06 | 2024-10-30 | Nxera Pharma Uk Limited | Biciklične aza spojine kot agonisti muskarinskega receptorja |
-
2023
- 2023-08-03 AR ARP230102050A patent/AR130114A1/es unknown
- 2023-08-03 PE PE2025000295A patent/PE20251236A1/es unknown
- 2023-08-03 JP JP2025505853A patent/JP2025526601A/ja active Pending
- 2023-08-03 EP EP25198643.6A patent/EP4663190A2/en active Pending
- 2023-08-03 TW TW112129182A patent/TW202416955A/zh unknown
- 2023-08-03 DK DK23757194.8T patent/DK4508045T3/da active
- 2023-08-03 KR KR1020257006895A patent/KR20250041066A/ko active Pending
- 2023-08-03 WO PCT/EP2023/071591 patent/WO2024028458A2/en not_active Ceased
- 2023-08-03 MD MDE20250179T patent/MD4508045T2/ro unknown
- 2023-08-03 LT LTEPPCT/EP2023/071591T patent/LT4508045T/lt unknown
- 2023-08-03 FI FIEP23757194.8T patent/FI4508045T3/fi active
- 2023-08-03 HR HRP20251427TT patent/HRP20251427T1/hr unknown
- 2023-08-03 CA CA3263797A patent/CA3263797A1/en active Pending
- 2023-08-03 CN CN202380057529.4A patent/CN119866336A/zh active Pending
- 2023-08-03 IL IL318739A patent/IL318739A/en unknown
- 2023-08-03 US US18/867,575 patent/US20250340531A1/en active Pending
- 2023-08-03 CR CR20250069A patent/CR20250069A/es unknown
- 2023-08-03 SI SI202330050T patent/SI4508045T1/sl unknown
- 2023-08-03 EP EP23757194.8A patent/EP4508045B1/en active Active
- 2023-08-03 RS RS20251164A patent/RS67422B1/sr unknown
- 2023-08-03 MA MA69856A patent/MA69856B1/fr unknown
- 2023-08-03 PT PT237571948T patent/PT4508045T/pt unknown
- 2023-08-03 ES ES23757194T patent/ES3050097T3/es active Active
- 2023-08-03 AU AU2023317835A patent/AU2023317835A1/en active Pending
-
2025
- 2025-01-31 DO DO2025000015A patent/DOP2025000015A/es unknown
- 2025-01-31 MX MX2025001312A patent/MX2025001312A/es unknown
- 2025-01-31 CL CL2025000299A patent/CL2025000299A1/es unknown
- 2025-02-28 CO CONC2025/0002413A patent/CO2025002413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK4508045T3 (da) | 2025-10-20 |
| CR20250069A (es) | 2025-05-26 |
| US20250340531A1 (en) | 2025-11-06 |
| EP4508045A2 (en) | 2025-02-19 |
| PE20251236A1 (es) | 2025-04-29 |
| DOP2025000015A (es) | 2025-04-08 |
| CA3263797A1 (en) | 2024-02-08 |
| PT4508045T (pt) | 2025-10-29 |
| ES3050097T3 (en) | 2025-12-19 |
| RS67422B1 (sr) | 2025-12-31 |
| AR130114A1 (es) | 2024-11-06 |
| AU2023317835A1 (en) | 2025-03-20 |
| JP2025526601A (ja) | 2025-08-15 |
| KR20250041066A (ko) | 2025-03-25 |
| MA69856B1 (fr) | 2025-10-31 |
| MX2025001312A (es) | 2025-05-02 |
| EP4663190A2 (en) | 2025-12-17 |
| CL2025000299A1 (es) | 2025-08-08 |
| MD4508045T2 (ro) | 2026-01-31 |
| CO2025002413A2 (es) | 2025-06-16 |
| HRP20251427T1 (hr) | 2025-12-19 |
| TW202416955A (zh) | 2024-05-01 |
| IL318739A (en) | 2025-03-01 |
| SI4508045T1 (sl) | 2025-11-28 |
| WO2024028458A2 (en) | 2024-02-08 |
| FI4508045T3 (fi) | 2025-11-13 |
| CN119866336A (zh) | 2025-04-22 |
| EP4508045B1 (en) | 2025-10-01 |
| WO2024028458A3 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4508045T (lt) | Muskarininio receptoriaus agonisto citrato druskos formos | |
| HRP20130468T1 (en) | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| IL281393A (en) | Formulations for oral administration of kappa opioid receptor agonists | |
| ZA200802586B (en) | Dihyrdogen phosphate salt of a prostaglandin D2 receptor antagonist | |
| LT4313945T (lt) | Kristalinė 5-meo-dmt hidrobromido druska | |
| IL281464A (en) | Crystal forms of a paranoid X receptor agonist | |
| EP4130005A4 (en) | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF | |
| IL312637A (en) | Treatment of liver disorders with a thr-β agonist | |
| EP4455141A4 (en) | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTALLINE FORM OF GLP-1 RECEPTOR AGONIST AND PROCESS FOR PREPARATION THEREOF | |
| EP4019496A4 (en) | SALT AND CRYSTAL FORM OF A COMPOUND WITH AGONISTIC ACTION ON S1P5 RECEPTOR | |
| EP4013398A4 (en) | IMPROVED METHOD FOR PRODUCING VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | |
| IL184395A0 (en) | Novel salt form of a dopamine agonist | |
| MY197142A (en) | Gonadotropin-releasing hormone receptor antagonist and use thereof | |
| GB2593902B (en) | Salt of a pharmaceutical compound | |
| GB202301180D0 (en) | Salt of a pharmaceutical compound | |
| EP4306516A4 (en) | NEW METHOD FOR THE PRODUCTION OF A SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONIST | |
| LT4041388T (lt) | Prostaglandino ep4 receptoriaus antagonisto junginiai | |
| EP4431488A4 (en) | PROCESS FOR PREPARING DOPAMINE HYDROCHLORIDE | |
| GB202211234D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB202309615D0 (en) | Muscarinic receptor agonists | |
| GB202305444D0 (en) | Muscarinic receptor agonists | |
| GB202003100D0 (en) | Salts and polymorphic forms of compound a | |
| CA3287403A1 (en) | Polymorph form of pitolisant hydrochloride | |
| GB201909012D0 (en) | Prostaglandin EP4 receptor agonist compounds | |
| GB201909004D0 (en) | Prostaglandin EP4 receptor agonist compounds |